<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798550</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00063210</org_study_id>
    <nct_id>NCT01798550</nct_id>
  </id_info>
  <brief_title>Enoxaparin Dosing in Obesity</brief_title>
  <official_title>Evaluation of Enoxaparin Dosing in Hospitalized Morbidly Obese Patients at an Academic Medical Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine an effective enoxaparin dosing strategy in
      medically ill, morbidly obese patients. This study will include adult patients greater than
      18 yrs of age being admitted to Grady Hospital in Atlanta, GA. Potentially vulnerable
      patients such as prisoners, children, and pregnant women will not be enrolled in the study.
      Study participants will be contacted in person by the study personnel once inclusion criteria
      are met. Written informed consent will be obtained in person while hospitalized. Once the
      patient is consented they will be given enoxaparin and blood samples will be drawn. The data
      collected will be from the electronic medical record which is accessed only with a username
      and password so it is not publicly available. The data will be identifiable upon collection
      and will be kept on a password protected file on a computer in a locked office. The data will
      be de-identified after data analysis and only the study personnel will have access to the
      code that links identifiers to subjects. A HIPAA waiver will be requested to access existing
      data in order to identify patients for enrollment. All data will be collected in an office in
      the hospital. The study participants' burden will be minimal and dependent only on time of
      consent process since morbidly obese patients would be receiving this blood sample collection
      regardless of their participation in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 15, 2016</completion_date>
  <primary_completion_date type="Actual">October 1, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group</measure>
    <time_frame>3-5 hours after at least 3rd dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Therapeutic Anti-Xa Level for Both Groups</measure>
    <time_frame>Assessed once after 3 consecutive enoxaparin doses (approx. 36 hours) and then daily if dose adjustments were indicated up to 30 days</time_frame>
    <description>Time to therapeutic Anti-Xa = time in hours from enoxaparin dose #1 to the first therapeutic Anti-Xa. The Anti-Xa was assessed 3-5 hours after at least three consecutive enoxaparin doses. If a dose adjustment was needed, the anti-Xa level was drawn four hours after the adjusted dose of enoxaparin was administered. Dose adjustments were made until a therapeutic level within goal range was obtained.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Median Steady State Anti-Xa Levels</measure>
    <time_frame>Assessed once after 3 consecutive enoxaparin doses (approx. 36 hours) and then daily if dose adjustments were indicated up to 30 days</time_frame>
    <description>The goal anti-Xa peak level range was defined as 0.5 - 1.1 International units/mL. The Anti-Xa was assessed 3-5 hours after at least three consecutive enoxaparin doses. If a dose adjustment was needed, the anti-Xa level was drawn four hours after the adjusted dose of enoxaparin was administered. Dose adjustments were made until a therapeutic level within goal range was obtained.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients Requiring Dose Adjustments to Achieve Therapeutic Anti-Xa Level</measure>
    <time_frame>Assessed once after 3 consecutive enoxaparin doses (approx. 36 hours) and then daily if dose adjustments were indicated up to 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Patients With Major and Minor Bleeding Events Prior to Achieving a Therapeutic Level</measure>
    <time_frame>Hemoglobin and platelets were assessed at baseline and daily as indicated while on study up to 30 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Reduced Dose (0.8 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose (1 mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 1 mg/kg (using total body weight) twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Twice daily dosing</description>
    <arm_group_label>Reduced Dose (0.8 mg/kg)</arm_group_label>
    <arm_group_label>Standard Dose (1 mg/kg)</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned treating with twice daily enoxaparin

          -  BMI &gt;= 40 kg/m2

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  CrCl &lt; 30 ml/min

          -  Pregnancy

          -  Prisoner

          -  Active bleeding

          -  Already received 3 consecutive doses of enoxaparin

          -  Use of therapeutic enoxaparin for more than 5 consecutive days within the last 3
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine L Kempton, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <results_first_submitted>October 7, 2017</results_first_submitted>
  <results_first_submitted_qc>October 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Christine Kempton, MD, MSc</investigator_full_name>
    <investigator_title>Associate Professor, Department of Pediatrics and Department of Hematology and Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Enoxaparin dosing</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Reduced Dose (0.8 mg/kg)</title>
          <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
        </group>
        <group group_id="P2">
          <title>Standard Dose (1 mg/kg)</title>
          <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reduced Dose (0.8 mg/kg)</title>
          <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
        </group>
        <group group_id="B2">
          <title>Standard Dose (1 mg/kg)</title>
          <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="45" upper_limit="62"/>
                    <measurement group_id="B2" value="56" lower_limit="46" upper_limit="63"/>
                    <measurement group_id="B3" value="56" lower_limit="45" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group</title>
        <time_frame>3-5 hours after at least 3rd dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Dose (0.8 mg/kg)</title>
            <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose (1 mg/kg)</title>
            <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Therapeutic Anti-Xa Level for Both Groups</title>
        <description>Time to therapeutic Anti-Xa = time in hours from enoxaparin dose #1 to the first therapeutic Anti-Xa. The Anti-Xa was assessed 3-5 hours after at least three consecutive enoxaparin doses. If a dose adjustment was needed, the anti-Xa level was drawn four hours after the adjusted dose of enoxaparin was administered. Dose adjustments were made until a therapeutic level within goal range was obtained.</description>
        <time_frame>Assessed once after 3 consecutive enoxaparin doses (approx. 36 hours) and then daily if dose adjustments were indicated up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Dose (0.8 mg/kg)</title>
            <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose (1 mg/kg)</title>
            <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Therapeutic Anti-Xa Level for Both Groups</title>
          <description>Time to therapeutic Anti-Xa = time in hours from enoxaparin dose #1 to the first therapeutic Anti-Xa. The Anti-Xa was assessed 3-5 hours after at least three consecutive enoxaparin doses. If a dose adjustment was needed, the anti-Xa level was drawn four hours after the adjusted dose of enoxaparin was administered. Dose adjustments were made until a therapeutic level within goal range was obtained.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="26.7" upper_limit="41.0"/>
                    <measurement group_id="O2" value="31.9" lower_limit="27.7" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Median Steady State Anti-Xa Levels</title>
        <description>The goal anti-Xa peak level range was defined as 0.5 – 1.1 International units/mL. The Anti-Xa was assessed 3-5 hours after at least three consecutive enoxaparin doses. If a dose adjustment was needed, the anti-Xa level was drawn four hours after the adjusted dose of enoxaparin was administered. Dose adjustments were made until a therapeutic level within goal range was obtained.</description>
        <time_frame>Assessed once after 3 consecutive enoxaparin doses (approx. 36 hours) and then daily if dose adjustments were indicated up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Dose (0.8 mg/kg)</title>
            <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose (1 mg/kg)</title>
            <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Median Steady State Anti-Xa Levels</title>
          <description>The goal anti-Xa peak level range was defined as 0.5 – 1.1 International units/mL. The Anti-Xa was assessed 3-5 hours after at least three consecutive enoxaparin doses. If a dose adjustment was needed, the anti-Xa level was drawn four hours after the adjusted dose of enoxaparin was administered. Dose adjustments were made until a therapeutic level within goal range was obtained.</description>
          <units>IU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.66" upper_limit="0.90"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.69" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients Requiring Dose Adjustments to Achieve Therapeutic Anti-Xa Level</title>
        <time_frame>Assessed once after 3 consecutive enoxaparin doses (approx. 36 hours) and then daily if dose adjustments were indicated up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Dose (0.8 mg/kg)</title>
            <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose (1 mg/kg)</title>
            <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Dose Adjustments to Achieve Therapeutic Anti-Xa Level</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients With Major and Minor Bleeding Events Prior to Achieving a Therapeutic Level</title>
        <time_frame>Hemoglobin and platelets were assessed at baseline and daily as indicated while on study up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Dose (0.8 mg/kg)</title>
            <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose (1 mg/kg)</title>
            <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Major and Minor Bleeding Events Prior to Achieving a Therapeutic Level</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, duration of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Reduced Dose (0.8 mg/kg)</title>
          <description>Enoxaparin 0.8 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
        </group>
        <group group_id="E2">
          <title>Standard Dose (1 mg/kg)</title>
          <description>Enoxaparin 1 mg/kg (using total body weight) twice daily
Enoxaparin: Twice daily dosing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine Kempton MD, MSc</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1900</phone>
      <email>ckempto@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

